Skip to main content
SpringerLink
Log in

Cost Effectiveness of Antituberculosis Interventions

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The treatment of tuberculosis (TB) is ranked as the most cost effective of all therapeutic programmes in terms of cost per year of life saved. Nevertheless, TB kills or debilitates more adults aged between 15 and 59 years than any other disease in the world; furthermore, about 2 to 4% of the burden of disease, 7% of all deaths and 26% of all preventable deaths are directly attributable to TB.

About one-third of the world’s population is infected with the TB bacillus. In the developing world, more women of childbearing age die from TB than from causes directly associated with pregnancy and childbirth. The death of adults in their prime, who are parents, community leaders and producers in most societies, causes a particularly onerous burden besides being a serious public health problem. In the poorest countries, where the magnitude of the TB problem is greatest, those TB control strategies that are economically feasible tend to be less effective. Therefore, in low and middle income countries, cost-effectiveness considerations aimed at prioritising resource allocation in the health sector in general, and in TB control programmes in particular, are of paramount importance.

Operationally, the main components of a TB control programme are: (i) detection and treatment of TB; and (ii) prevention of TB through BCG vaccination and chemoprophylaxis. Priority should be given to ensuring that TB patients complete their prescribed course of chemotherapy. Adequate treatment is the most effective way of preventing the spread of TB and the emergence of drug resistance. This article reviews evidence of the effectiveness and cost effectiveness of different approaches to TB care, particularly those that are applicable to low income countries, in both HIV-infected and noninfected patients. Financial implications and ways to implement directly observed therapy for TB in large urban areas are discussed, and the need to address some relevant operational issues is highlighted. The current role of chemoprophylaxis and BCG vaccination is also reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Murray CJ, Jonghe E, Chum HJ, et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305–1308

    Article  PubMed  CAS  Google Scholar 

  2. Raviglione MC, Sudre P, Rieder HL, et al. Secular trends of tuberculosis in Western Europe. Bull World Health Organ 1993; 71: 297–320

    PubMed  CAS  Google Scholar 

  3. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65: 6–24

    PubMed  CAS  Google Scholar 

  4. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72: 1–6

    Article  PubMed  CAS  Google Scholar 

  5. Grzybowsi S. Tuberculosis in the third world. Thorax 1991; 46: 689–691

    Article  Google Scholar 

  6. Dolin PJ, Raviglione MC, Kochi A. Estimates of future global tuberculosis: morbidity and mortality. MMWR Morb Mortal Wkly Rep 1993; 42: 961–964

    Google Scholar 

  7. WHO. Press release. Geneva: WHO, 1994 Jan 8

    Google Scholar 

  8. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273: 220–226

    Article  PubMed  CAS  Google Scholar 

  9. Sutherland I, Fayers PM. The association of the risk of tuberculosis infection with age. Bull Int Union Tuberc 1975; 50: 70–81

    PubMed  CAS  Google Scholar 

  10. Bloom BR, Murray CJ. Tuberculosis: commentary on a reemergent killer. Science 1992; 257: 1055–1064

    Article  PubMed  CAS  Google Scholar 

  11. Snider DE, La Montagne JR. The neglected global tuberculosis problem: a report of the 1992 World Congress on tuberculosis. J Infect Dis 1994; 169: 1189–1196

    Article  PubMed  Google Scholar 

  12. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359–1374

    Google Scholar 

  13. Leowsky J. The role of short-course chemotherapy in National Tuberculosis Control Programmes in developing countries. WHO Regional Office for the Western Pacific, Working Group on Short-Course Chemotherapy for Tuberculosis. 1988 Aug 22-6

    Google Scholar 

  14. Fox W. The modern management and therapy of pulmonary tuberculosis. Proc R Soc Med 1977; 70: 4–15

    PubMed  CAS  Google Scholar 

  15. Resistant tubercle bacilli [editorial]. Lancet 1953; 2: 237

  16. Frimodt-Moller J, Parsthosanathy R, Achonyulu GS, et al. Domiciliary drug therapy of pulmonary tuberculosis in a rural population in India. Tubercle 1968; 49 Suppl.: 22–23

    Article  PubMed  Google Scholar 

  17. Kent PW, Fox W, Miller AB, et al. The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trial with those achieved by the routine treatment services. Tubercle 1970; 51: 24–38

    Article  PubMed  CAS  Google Scholar 

  18. Teklu B. Reasons for failure in treatment of pulmonary tuberculosis in Ethiopians. Tubercle 1984; 65: 17–21

    Article  PubMed  CAS  Google Scholar 

  19. Haynes RB. Determinants of compliance: the disease and mechanics of treatment. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Baltimore (MD): Johns Hopkins University Press, 1979

    Google Scholar 

  20. Kilpatrick GS. Compliance in relation to tuberculosis. Tubercle 1987; 68: 31–32

    Article  PubMed  CAS  Google Scholar 

  21. Fox W. General considerations on the choice and control of chemotherapy in pulmonary tuberculosis. Bull Int Union Tuberc 1972; 47: 51–71

    Google Scholar 

  22. East African/British Medical Research Council Study. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977; 116: 3–8

    Google Scholar 

  23. Second East African/British Medical Research Council Study. Controlled clinical trials of four 6-month regimens of chemotherapy for pulmonary tuberculosis: second report. Am Rev Respir Dis 1976; 114: 471–475

    Google Scholar 

  24. Third East African/British Medical Research Council Study. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report. Am Rev Respir Dis 1978; 118: 39–48

    Google Scholar 

  25. Singapore Tuberculosis Service/British Medical Research Council. Long term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133: 779–783

    Google Scholar 

  26. East African/British Medical Research Council. Controlled clinical trial of five short-course (4 month) chemotherapy regimens in pulmonary tuberculosis: second report of the 4th study. Am Rev Respir Dis 1981; 123: 165–170

    Google Scholar 

  27. Kreis B, Pretet S, Birenbaum J, et al. Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuberc 1976; 51: 71–75

    PubMed  CAS  Google Scholar 

  28. Snider DE, Graczyk J, Bek E, et al. Supervised six-month treatment using isoniazid, rifampin and pyrazinamide with and without streptomycin. Am Rev Respir Dis 1984; 130: 1091–1094

    PubMed  CAS  Google Scholar 

  29. Coombs DL, O’Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990; 112: 397–406

    Google Scholar 

  30. Castelo A, Jardim JR, Goihman S, et al. Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis. Lancet 1989; 2: 1173–1176

    Article  PubMed  CAS  Google Scholar 

  31. Hong Kong Tuberculosis Treatment Services/British Medical Research Council Study. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Tubercle 1975; 56: 81–96

    Article  Google Scholar 

  32. Hong Kong Chest Service/British Medical Research Council Study. Controlled trial of 6- and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong: results up to 30 months. Am Rev Respir Dis 1977; 115: 727–732

    Google Scholar 

  33. Singapore Tuberculosis Service/British Medical Research Council. Five year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase of pulmonary tuberculosis. Am Rev Respir Dis 1988; 137: 1147–1150

    Google Scholar 

  34. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 1991; 143: 707–712

    Google Scholar 

  35. Hong Kong Tuberculosis Treatment Services/British Medical Research Council Study. Controlled trial of 2,4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991; 143: 700–706

    Google Scholar 

  36. Prabhaker R. Fully intermittent six month regimens for pulmonary tuberculosis in South India. Bull Int Union Tuberc 1987; 62 (3): 21–23

    Google Scholar 

  37. Anastasatu C, Bereca O, Corlan E. Pilot study of short course 3 plus 3 intermittent chemotherapy in previously untreated smear positive tuberculosis. Bull Int Union Tuberc 1982; 52: 1–19

    Google Scholar 

  38. Cohn DL, Catlin BJ, Peterson KL, et al. A 62-dose, 6-month therapy for pulmonary and extra-pulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112: 407–415

    PubMed  CAS  Google Scholar 

  39. Ellard GA, Ellard DR, Allen BW, et al. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986; 133: 1076–1080

    PubMed  CAS  Google Scholar 

  40. Acocella G. Quality control of antituberculosis drugs: human bioavailability studies. Bull Int Union Tuberc Lung Dis 1989; 6 (1): 38–40

    Google Scholar 

  41. International Union Against Tuberculosis and Lung Disease. Antituberculosis regimens of chemotherapy: recommendations from the committee on treatment. Bull Int Union Tuberc Lung Dis 1988; 63 (2): 60–64

    Google Scholar 

  42. Advisory Committee for the Elimination of Tuberculosis (ACET) Recommendations. Tuberculosis and human immunodeficiency virus infection. MMWR Morb Mortal Wkly Rep 1989; 38: 236–250

    Google Scholar 

  43. European Tuberculosis Treatment Group. ENTA, EEC-Tuberculosis Concerted Actions. Tuberculosis in HIV-infected patients: a multicentric comparative study of a three versus a four-drug regimen. Proceedings of the Ninth International Conference on AIDS/Fourth STD World Congress; 1993 Jun 6–11: Berlin. London: Wellcome Foundation, 1993

    Google Scholar 

  44. Dailey C, Rudoy I, Small R, et al. Treatment of tuberculosis in HIV-infected patients with a six-month regimen. Tubercle and Lung Dis 1994; 75 (1 Suppl.): 8S–9S

    Article  Google Scholar 

  45. Kassim S, Sassan-Morokro M, Doorly R, et al. Prospective study of pulmonary tuberculosis and HIV-1 and HIV-2 infections, Abidjan, Cote DT voire. Proceedings of the Eighth International Conference on AIDS/Third STD World Congress; 1992 Jul 19–24: Amsterdam. Amsterdam: Congrex, 1992

    Google Scholar 

  46. Vitti W, Vieira MAM, Kritski AL. Retrospective study of short-course anti-TB therapy in HIV-infected IVDUs, Santos, Brazil. Proceedings of the Eighth International Conference on AIDS/Third STD World Congress; 1992 Jul 19–24: Amsterdam. Amsterdam: Congrex, 1992

    Google Scholar 

  47. Perrone C, Ghoubontni A, Leport C, et al. Should pulmonary tuberculosis be an AIDS-defining diagnosis in patients infected with HIV? Tuber Lung Dis 1992; 73: 39–44

    Article  Google Scholar 

  48. Perriens JH, St. Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332 (12): 779–784

    Article  PubMed  CAS  Google Scholar 

  49. Alwood K, Keruly J, Moore-Rice K, et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994; 8: 1103–1108

    Article  PubMed  CAS  Google Scholar 

  50. Walker AT, O’Brien RJ. Retrospective survey of treatment of tuberculosis in persons with AIDS [abstract]. Am Rev Respir Dis 1990; 141 Suppl. A: 68

    Google Scholar 

  51. Okwera A, Whalen C, Byekwaso F, et al. Randomized trial of thiacetazone and rifampicin containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323–1328

    Article  PubMed  CAS  Google Scholar 

  52. Canueto J, Torres TM, Escribano JC, et al. Follow-up of AIDS patients with tuberculosis after completion of anti-tuberculosis therapy: is indefinite therapy advisable? Proceedings of the Eighth International Conference on AIDS/Third STD World Congress; 1992 Jul 19–24: Amsterdam. Amsterdam: Congrex, 1992

    Google Scholar 

  53. Holt E, Cantave M, Johnson M, et al. Efficacy of supervised, intermittent, short-course therapy of tuberculosis in HIV infection. Proceedings of the Ninth International Conference on AIDS/Fourth STD World Congress; 1993 Jun 6–11: Berlin. London: Wellcome Foundation, 1993

    Google Scholar 

  54. Batungawanayo J, Taelman H, Dhote R, et al. Pulmonary tuberculosis in Kigali, Rwanda: impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 1992; 146: 53–56

    Google Scholar 

  55. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet 1993; 342: 332–337

    Article  PubMed  CAS  Google Scholar 

  56. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with ‘standard’ chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750–755

    Article  PubMed  CAS  Google Scholar 

  57. Eriki PP, Okwera A, Aisu T, et al. Influence of human immunodeficiency virus (HIV) on expression of tuberculosis in Kampala, Uganda [abstract]. Am Rev Respir Dis 1990; 141 Suppl. A: 261

    Google Scholar 

  58. Elliot AM, Luo A, Tembo G, et al. The impact of HIV on tuberculosis in Zambia: a cross-sectional study. BMJ 1990; 301: 412–415

    Article  Google Scholar 

  59. Gonzalez-Montaner LJ, Mosca C, Abbate E, et al. Treatment of tuberculosis (TB) in patients with AIDS and intravenous drug abusers (IVDA) in Buenos Aires (Argentina) [abstract]. Am Rev Respir Dis 1992; 145 Suppl. A: 107

    Google Scholar 

  60. Small P, Schecter G, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289–294

    Article  PubMed  CAS  Google Scholar 

  61. Zamora L, Gatel JM, Mallolas J, et al. Treatment of tuberculosis in HIV infected patients. Proceedings of the Sixth International Conference on AIDS; 1990 Jun 2–24: San Francisco. San Francisco: University of California, 1990

    Google Scholar 

  62. Carton JA, Carcaba V, Maradona JA, et al. Successful antituberculosis treatment with various drug regimens in patients with HIV infection. Proceedings of the Fifth International Conference on AIDS; 1989 Jun 4–9: Montreal. Ottawa: International Development Research Centre, 1989

    Google Scholar 

  63. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849–854

    PubMed  CAS  Google Scholar 

  64. Rosenblum LS, Castro KG, Dooley S, et al. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990. Ann Intern Med 1994; 121: 786–792

    PubMed  CAS  Google Scholar 

  65. Panamerican Health Association. Association between HIV and tuberculosis: technical guide. Bull Pan Am Health Organ 1993; 27 (3): 297–310

    Google Scholar 

  66. WHO. Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes. Geneva: WHO, 1991: Report No. 91.161

    Google Scholar 

  67. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359–1374

    Google Scholar 

  68. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can’t afford not to try it. N Engl J Med 1993; 328: 576–579

    Article  PubMed  CAS  Google Scholar 

  69. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986; 134: 355–363

    Google Scholar 

  70. Consensus Conference on Tuberculosis. Chest 1985; 87 Suppl.: I15S-49S

  71. WHO. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO, 1993

    Google Scholar 

  72. Weiss ES, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179–1184

    Article  Google Scholar 

  73. Centers for Disease Control/American Thoracic Society. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep 1993; 42 (RR-7): 1–8

    Google Scholar 

  74. Centers for Disease Control. Approaches to improving adherence to antituberculosis therapy — South Carolina and New York, 1986–1991. MMWR Morb Mortal Wkly Rep 1993; 42 (4): 74–81

    Google Scholar 

  75. DiFerdinando GT, Klein SJ, Novick LF. Directly observed treatment of tuberculosis. N Engl J Med 1993; 329 (2): 135–136

    Article  PubMed  Google Scholar 

  76. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet 1994; 343: 647–648

    Article  PubMed  CAS  Google Scholar 

  77. Styblo K, Chum HJ. Treatment results of smear-positive tuberculosis in the Tanzania National Tuberculosis and Leprosy Programme: standard and short-course chemotherapy. Proceedings of the XXVIth World Conference on Tuberculosis and Respiratory Diseases; 1986 Nov 4–7: Singapore. Tokyo: Professional Postgraduate Services, 1987

    Google Scholar 

  78. Barnum HN. Cost savings from alternative treatments for tuberculosis. Soc Sci Med 1986; 23 (9): 847–850

    Article  PubMed  CAS  Google Scholar 

  79. Thompson HJ, Snider DE, Farer LS. Variations in national health care practices and behaviors and their influence on international research. Int J Epidem 1985; 14: 457–462

    Article  CAS  Google Scholar 

  80. Kamolratanakul P, Chunhaswasdkul B, Jittinandana A, et al. Cost-effectiveness analysis of three short-course anti-tuberculosis programmes compared with a standard regimen in Thailand. J Clin Epidemiol 1993; 46: 631–636

    Article  PubMed  CAS  Google Scholar 

  81. Joesoef MR, Remington PL, Jiptoherijanto PT. Epidemiological model and cost-effectiveness analysis of tuberculosis treatment programmes in Indonesia. Int J Epidemiol 1988; 18: 174–179

    Article  Google Scholar 

  82. Societe Francaise de Pneumologie. Recommandations pour le traitment de la tuberculose en France. Rev Mai Respir 1984; 1: 59–62

    Google Scholar 

  83. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis: a code of practice. BMJ 1983; 287: 1118–1121

    Article  Google Scholar 

  84. Comstock GW, Woolpert SF, Baum C. Isoniazid prophylaxis among Alaskan Eskimos: a progress report. Am Rev Respir Dis 1974; 110: 195–197

    PubMed  CAS  Google Scholar 

  85. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res 1970; 17: 28–106

    Google Scholar 

  86. Thompson NJ. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of followup in the IUAT trial. Bull World Health Organ 1982; 60: 555–564

    Google Scholar 

  87. Snider DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579–1583

    Article  PubMed  Google Scholar 

  88. Fitzgerald JM, Gafni A. A cost-effectiveness analysis of the routine use of isoniazid in patients with a positive Mantoux skin test. Am Rev Respir Dis 1990; 142: 848–853

    PubMed  CAS  Google Scholar 

  89. American Academy of Pediatrics. Report of the Committee on Infectious Diseases. 22nd ed. Elk Grove (IL): American Academy of Pediatrics, 1991: 487–508

    Google Scholar 

  90. Grosset JH. Present status of chemotherapy for tuberculosis. Rev Infect Dis 1989; 11: S347–S352

    Article  PubMed  Google Scholar 

  91. Centers for Disease Control. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992; 41: 59–71

    Google Scholar 

  92. Murray C, Styblo K, Rouillon A. Tuberculosis. In: Jamilson D, Mosley WH, Measham A, et al., editors. Disease control priorities in developing countries. New York: Oxford University Press, 1993: 233–259

    Google Scholar 

  93. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 545–550

    Article  PubMed  CAS  Google Scholar 

  94. Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644–1650

    Article  PubMed  CAS  Google Scholar 

  95. Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis 1992; 15: 540–547

    Article  PubMed  CAS  Google Scholar 

  96. Centers for Disease Control. Purified protein derivative (PPD)-tuberculin anergy and HIV: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR Morb Mortal Wkly Rep 1991; 40: 27–32

    Google Scholar 

  97. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119 (3): 194–198

    PubMed  CAS  Google Scholar 

  98. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268–272

    Article  PubMed  CAS  Google Scholar 

  99. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta analysis of the published literature. JAMA 1994; 271 (9): 698–702

    Article  PubMed  CAS  Google Scholar 

  100. Tuberculosis Prevention Trial, Madras. Trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 1980; 72 Suppl.: 1–74

    Google Scholar 

  101. Wheeler JG, Rodrigues LC, Diwan V. Global challenge of tuberculosis [letter]. JAMA 1994; 272 (10): 765

    Article  PubMed  CAS  Google Scholar 

  102. Barnum HN, Tarantola D, Setaidy IF. Cost-effectiveness of an immunization programme in Indonesia. Bull World Health Organ 1980; 58: 499–503

    PubMed  CAS  Google Scholar 

  103. A Joint Statement of the WHO Tuberculosis Programme and the Global Programme on AIDS, and the International Union Tuberculosis and Lung Disease (IUATLD). Tuberculosis preventive therapy in HIV-infected individuals. Wkly Epidemiol Rec 1993; 68: 361–368

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Rua Botucatu 740, 04023-062, Sao Paulo SP, Brazil

    Adauto Castelo, Pedro A. Mathiasi, Roberto Iunes, Afranio L. Kritski, Margareth Dalcolmo & Fernando Fiuza de Melo

  2. Centre for Health Economics, University of York, York, England

    Michael Drummond

Authors
  1. Adauto Castelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pedro A. Mathiasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Iunes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Afranio L. Kritski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Margareth Dalcolmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fernando Fiuza de Melo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael Drummond
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castelo, A., Mathiasi, P.A., Iunes, R. et al. Cost Effectiveness of Antituberculosis Interventions. Pharmacoeconomics 8, 385–399 (1995). https://doi.org/10.2165/00019053-199508050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199508050-00003

Keywords

Search

Navigation